stockmarket

NRx Pharmaceuticals Stock Surges After Progress on Covid-19 Treatment




By Sam Boughedda

Investing.com —  NRX Pharmaceuticals (NASDAQ:) shares surged Tuesday after it reported 2 new updates related to its treatment for Covid-19 respiratory failure. 

The shares rallied 60.9% to $10.91 on Tuesday. However, they are still down 55.87% for the year to date. 

The company said a revamped Investigational New Drug module on the manufacturing of Zyesami was proposed to the U.S. Food and Drug Administration (FDA), including documentation that confirmed Nephron Pharmaceuticals can supply the treatment on a commercial scale. 

The module will be utilized as a part of the FDA’s rolling review process supporting the New Drug Application for ZYESAMI.

NRx’s CEO and Chairman, Prof Jonathan Javitt, said the company is continuing “efforts to ensure that NRx has the supply and logistics in place to provide ZYESAMI to patients where it is granted regulatory approval.”

In addition, the company has also been notified that a European Qualified Person Auditor has concluded an examination at a separate manufacturing facility with no adverse findings. 

NRx is awaiting a Qualified Person declaration that the EU regulator needs to release ZYESAMI. The audit was completed ahead of the company submitting ZYESAMI to EU and United Kingdom health authorities.

 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.